DexCom (DXCM) 2 May 192019 Q1 Earnings call transcript

Company Profile

Participants

Matt Dolan	Vice President, Corporate Development
Kevin Sayer	Chairman, President and Chief Executive Officer
Quentin Blackford	Executive Vice President and Chief Financial Officer
Steve Pacelli	Executive Vice President of Strategy and Corporate Development
Jason Bradford	Raymond James
Robbie Marcus	JP Morgan
Danielle Antalffy	Leerink
J. P. McKim	Piper Jaffray
David Lewis	Morgan Stanley
Joanne Wuensch	BMO Capital Markets
Margaret Kaczor	William Blair
Jeff Johnson	Baird
Ryan Blicker	Cowen
Chris Pasquale	Guggenheim
Raj Denhoy	Jefferies
Ravi Misra	Berenberg Capital
Matt Taylor	UBS
Steve Lichtman	Oppenheimer
Suraj Kalia	Northland Securities

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the DexCom First Quarter 2019 Earnings Release Conference Call. My name is Adrienne and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session. [Operator Instructions] Please note this conference is being recorded. call Matt the turn now over Dolan. to I'll Dolan you begin. may Matt

Matt Dolan

DexCom's and XXXX operator, you, first welcome Thank to quarter earnings call.

Our Corporate Chairman, update Pacelli, President President, President and a Kevin from from Quentin Sayer, Steve who and and Development. Executive financial with Strategy quarter, of provide Vice our a the summary agenda will Vice of then outlook our by review CFO; Executive Blackford, and and begin CEO, followed DexCom's a strategic

will open At an the we follow-up the call ask Following analysts and questions. remarks, our Safe can themselves Harbor. everyone opportunity that, that available a are up for your question participating that our to the provide prepared so slides Presentations we let's and we Please time, for website review to also to there note limit one on the Investor page. DexCom Relations performance With Events our today. on related first quarter

by reports actual XX-Q any update Report detailed other presentation such actual results. Exchange made after cause date date Annual on currently subject those on forward-looking anticipated hereof, differ any to statements. of presentation forward-looking information Some obligation statements. assume could The this in actual expressed by are quarterly these and with in of expectations of event, Form and that the no statements operating factors we Commission. are may strategies, statements implied as from and to in law, to beliefs the DexCom, Form differ based XX-K, and All of filings statements on Except statements conform results uncertainties, competition, forward-looking risks materially from this available various statements and plans statements the about are included management's could to materially as These constitute those and to the future forward-looking products, results make forward-looking these intentions, call today's performance. or reflect or and required in DexCom's that we Securities will to forward-looking the

a discuss have noted measures non-GAAP non-GAAP metrics with that in during measures call, this references based in been on otherwise additional isolation results of superior results are the prepared Unless GAAP to portion our respect to of Please will in be a these accordance we release Relations for and Additionally, presented GAAP. with the financial as for basis. The prepared certain most with GAAP tables of results. to substitute to all directly our measure. and accordance their financial considered should our cash or Investor in reconciliation not information presentation refer to not or comparable earnings website a our the financial

I Kevin. turn Now, will over it to

Kevin Sayer

you joining Thank you for everyone and us. thank Matt,

XXXX that start a to off of experienced our XXXX, continuing into the we in great momentum are We in much with first quarter.

grew XXXX. we're OUS the a demonstrating demonstrating with headwinds DexCom new a above both good two million, broad revenues we're quarter in by over pricing track is $XXX that this expand as in strong XX% access increase this very quarter to mind, clinical to technology spent we particularly drive businesses Company our toward to XXXX. expense First CGM target U.S. the demand more was the performance awareness revenue of and We've cost doubling our operating meet have our expectations, of outpacing in that control than capacity growth the Once both GX From a by well absorb developing demand we existing innovative confident long-term first patients. is growing for our CGM. real again, build, based, on growth volumes and we results as and strong drove even rollout increased improve the anticipated. goal and among And as times. GX years outcomes. the increase of world as end We to expense With remain perspective, positioned of

frequency demonstrate the world true data of patient Low first provides actionable the has warning a decrease used. value among showed but of we only dangerous been on We the the in a a achieved our CGM. real feature, Soon not In in users we continue advance hypoglycemia the to quarter, regardless that further this this seen of GX hypoglycemia that have effectiveness Alert with an of GX, low, believe which in outcomes Urgent users demonstrates screened

follow once share again to base. arrange better correlation adolescents the the highlighting children and We between of show time importance and users our user for and also of feature apps diabetes, DexCom with this

as teams such in demand year patients’ benefits meet that as that are the of to customers, cared be clinical our to and we’re quarter great for especially the experiencing to customers. for. awareness fundamental we understand we case clock clinicians ability first outcomes can serve us To and clinicians the reputation contributed with improvement and of increasing forth every of Technology, among importance these and behalf. DexCom’s global bring working We As necessity CGM patient. these are each you on capitalize saw around document the have with to going the our around your can make must CGM certain and is and payers the challenges. allow reconfirm in our our process sometimes The This lives DexCom’s kind also burden demand back sure in on the

progress, be able support improvements. of demand productivity well progressing As financials. quarter increase several quarter, on meaningful review significant we of with the will call this will to that outlook I who pleased provide the outlook revenue turn first a Quentin as to we're showing XXXX. to areas our over very the for the level strength of our as our customer the and CGM now detail of are our Considering initiatives that DexCom’s expand well believe I introduced infrastructure to

Quentin Blackford

Kevin. you, Thank

I and reminder, as reconciliations discussed IR release Today, a metrics in on a website. As noted, will presented be earnings basis our financial business that of revenues revenues continued and absolute watermark company over found of be GAAP last highlighted $XXX.X of XX% dollar non-GAAP CGM expectations we on of growing impact respectively million currency constant tracking can unless the grew least revenues strong revenue first today representing Geographically, quarter otherwise to quarter XX% as Year. basis for that a first quarter the the of XX% growth today's for growth. growth first the to both XXXX. compared awareness for of XXXX the on the representing and $XXX.X million we reporting a long-term and well in XX% U.S. $XX our towards Clearly, million year. Investor worldwide the at International into the total the XX% Day of excluding at on quarter, that in XXXX, a international the or XX% same of New currency high late reported basis demonstrated for

have of profit to shifting to DexCom’s consisting at was and seen expectations improved the or $XXX.X We pharmacy our XX.X% quarter sales. and to CGM gross the access Our seek to initiative year, to years. Margin drive U.S. of from was capacity have incremental the what success mix consistent XXXX continued scale first was as XXXX, we start the with shift XXXX impacted with significant prior continued prioritize and international of and quarter negatively expansion by we fourth towards in seen infrastructure, investments business. gross drive we the in to Relative the first the sequential as continue we decline channel The million our this in of pharmacy quarter will

in some new progresses As pressure to with the demand speed to the These out system to as will strategic for capacity and with the investments the compares of of of continued the We XXXX quarter, access the expense increase margins year the exit in allow compared of additional to and year same putting the year for automation expenses the as process remain $XXX.X This greater of environment million to future first over ramp proactive Operating now us million million significant leverage Beginning last flexibility $XXX.X on transmitter accelerating year is year. to the to in in year gross into growth the demand. approaching margins. quarter loss continues to meet bring provided XXXX operating We pricing to in a expect to same prior and revenue growing uncertainties costs margins our favorably XX% was expectations, Operating with introduction XXXX. the to were be gross year. of continue the push capacity with XX% up gross confident exceed improvements to our which navigate $XX.X over CGM. quarter which implementation for ability and from resulting million as of a us to manufacturing quarter GX XX%. we we long-term. first payers period an our we're the XX% our compared increase in XX% reflects in the $X.X

for the improved first discipline EBITDA in quarter first was or compared revenue for XXXX year. XXXX. revenue the Our quarter from of of basis resulted prior X.X% operational million margins million point to in operating Adjusted of improvement $XX.X a X.X% or $X.X the

great As these first margin our and drive we operating to said quarter target our significant EBITDA opportunity XXXX, an adjusted in reflect toward there's we both throughout that towards leverage long-term believe goals. operating progress

business, we to at leverage the but CGM remain of ahead, the in that the the of this application our pursuing lies not also are confident our new we markets. only in expense not growth However, core business, for opportunity technology

continue maximize and potential. long-term to to our initiatives, in will DexCom's strategic invest pipeline R&D We opportunities in order these other

against $X.XX the approximately net remains and balance our borrowing having or billion cash no was in $X.X our and Our loss of $XXX equivalents credit. ended sheet with million strong and $X.X million share line quarter revolving per

$XX CapEx As the and quarter. we capacity continue prioritize of expansion to manufacturing first our initiatives into to add automation million which investment mentioned, will of in

are remainder to of quarter XX%. the that $XX billion of billion year, demand for million DexCom the at real-time full-year to expectations revenue first revenue our are of approximately growing the and $X.XX by our performance for we given the we $X.X seeing now of XX% the reported strength reflecting CGM, growth and total year, increasing anticipate Looking

XX%. for year the approaching of XX% in margins operating EBITDA original approximately We to As the I XX%. the XXXX showing mentioned target margins approximately year our of previously, to improvement now look margins meaningful half with remain we to X% anticipate exit of expect we comfortable full gross XX% year as back approximate adjusted and of

up our below well benefits. approximately I operations We original efforts estimate. scale setting been now demonstrating in significant the million restructuring employees ground the We've the to $XX over Manila. come XXX and now and update. efficiency call indications Steve half at now extremely the to in Philippines in $XX for with with early are the restructuring majority progressing pleased turn the Our with cost to slightly that, first in associated now With the for nearly expect on strategic related will and year a with

Steve Pacelli

you, Thank Quentin.

As quarter in stood also for front and Diabetes dramatically, DexCom utilized international and studies like indicates our first conference awareness or annual the ATTD from In in and time center presentations in demand for Treatments CGM Technologies but in February, at leaders diabetes real products community. UK and performance not Australia. only the in the Advanced to the increase numerous DexCom U.S., key clinical with markets Germany, continues global

rollout can attendance key global enhancement of and in our a platform. XXXX. excitement efforts As genuine course objective the GX is support, around app strategic anyone remained GX in of decision The toward attest, there

noted, Kevin are the XXXX. doubling GX of As capacity end by we

come, and Given continue platform we as in track GX, product brings, on certain GX for of we or significant level to our function product. next gen late for in many initial ease-of-use and markets DexCom rollout the to beyond that even system a years are for the we the production GX also of launch progress to the finalizing performance GX push XXXX toward a Yet teams early our XXXX GX as making of launch. remain expect

significantly a and DexCom, wearable. entirely healthcare meets one be for across CGM therapeutic fully extends one-piece the form leadership extended cost iCGM continued further will an the that standards GX reminder, sense utilizing disposable new platform landscape. reduced a our a and wear saving to present in outcomes Strong factor with As themselves

General the we deployment broad Well, quarters, CGM is discussed there know in for distribution diabetes, Markets. we have different in an in require announce now Manager since particularly channels. and non-intensive investment wellness. as these application time completely areas effort, several New of focus I'm opportunities II and and in order will that models In leave to in appointed pleased Dolan, diabetes, these increased gestational this that usage For have potential overall pre-diabetes, hospital type business Matt to we

Coming dedicated are a leader our involvement and development you these there Matt aware, growth confident key initiatives to choice, are to is we his having for we continue of leverage multiple that and with designation. advocates back insulin the ourselves already business, efforts. of proven we the relations principle our to of investor are early is guide corporate and iCGM to have delivery with DexCom. people he patient players, established the team many and core will As great partnerships and right be interoperability

We progress a forward products look few connected are and over these the from XX of the seeing months. significant this collaboration of launch to

it this and pass With ready to are the patients innovative proud products We are back we at of center progress. to stands of these our especially stand prone I DexCom as that, diabetes for that will minimize management Kevin. burden the

Kevin Sayer

exciting to Thanks thank put much our manufacturing, markets customer our leading the the on to have team, DexCom increase in core to to continued revenue know technology our way our performance in the technology obviously people we exploring meantime, together growth, Steve. team the believe pleased in incredibly personal are to quarter an work and we we attack Matt? Q&A. hard who high. need are business, of are CX. not support, but to we and to R&D with possible technology our cost-based big this from is increasing bring a CGM, you. as start on the to evidence new the the revenue GX platforms markets real-time with populations. only as With these the advancement positioned see very applications sensor in success, everybody that guidance. annual increasing and significant group and of are up that great of you’re prepared the with capitalizing DexCom's we working to DexCom and to clinical benefit My at to I very working the for beyond. first so of expectations we our call commercial to truly actively In we are for another for momentum the a are well summary, would are We additional possible This very diabetes number like We lot now high In comparability. year with year open up we

Matt Dolan

Kevin. Thank you,

question to we reminder, and themselves follow-up. a our As limit only one one ask Operator? audience to

Operator

Thank you.

now from question will Our question-and-answer session. being We the Instructions] [Operator James. Raymond first comes from Bradford Jason

line Your is open.

Jason Bradford

follow-up So, upfront related I'll question my ask here. and

growth then for the a migrating second, to in but the of realize to should initial terms still guidance? million pricing pharmacy, benefits be cost receiver the setting, in I the was And strong. First Quentin just new imply to et pharmacy the what about into cetera. in a that mix baked international guidance existing headwinds be the inherent continues quite due XXX Is what move the to users to in lower assumed

is And would would question dynamic incremental new you move patient the that you around think any in great? color my pharmacy growth Do be to pharmacy the the adds? stimulated the in is. quarter So provide

Quentin Blackford

your over in effort to with we to about points place change Jason, it that's it out that the pharmacy think course for we year a and yes, the there. setting like how the about million their call that's channel playing talked got XXX would. to of we've no consorted So, the on the about consistent so anticipated Obviously, year, move just the original initial still expectations we that

more patient the am point And driver. easy I a our channel in the access you makes at when the look there's and growth certain of Company, growth certain question new folks, the overall of patient that's convenient new for no pharmacy Your part driver I'm you more that on the growth, volume. primary know that is

So I connected. am it’s sure

Operator

next America. our Travis question And from comes Steed of Bank from

Your line is open.

Travis Steed

full QX year. at XX% looking for Just of revenue, the just seasonality is it seems your QX typical

about guiding for you're Just trying to a to than that XXXX. million think about suggests XXX more

XXXX? just that consider you So model should have? anything our as is conservatism there we we the is that Or typical else

Kevin Sayer

I talked to quarter. in see great being late our with bit that that new the the fourth think March, in was in expected right upside of by a outcome, their the had think about early really back really a came a at about folks next a lot call, expectation it month through way the the came shared quarter. may of great time, we about the strength patient I saw talked the that end those on day few recall the last We the quarter in that through XX% of signal and of was but things at be the and point in up that the quarter, driven second we back surprise. you additions know bit end of ahead we coming We in and reorder if a

more the other see channel into to just to Medicare business different of commercial to to the which faster of I overall very we revenue mind and continue and all the have move we seasonal to bigger that, the thing continues keep those as that generally pharmacy might a part year. become grow seasonality as is than around the more have early business them, in think as OUS continue patterns in business, the

know of all just that set year. expectations around different in there, as thoughtful what you signal for the mix math the out of indicate, laid your in the to business be of some of trying not we to we're shifts full trying being mindful the the we're Certainly would So, those dynamics we anything, but business.

Travis Steed

correctly, roughly with you're you make exiting I XX% want sure margin. then, heard gross the I And to year

on next is bit sustainable year? get on you needed? going it does a of Just pricing, info give there? to And that more flexibility give how more into you're also little us if kind bit And little

Kevin Sayer

Yes.

by So, I is ability year always into in had this with the get -- future. the XX% end is line to around that number gross progression of think margin the the we've our into that plan

could that to the we in with that play day we as to into go mix the have OUS investor becomes challenges out significant. path north per XX% or and arguably patient, to envision take our move headwinds to the continue revenue You you then that back pharmacy continue up more laid we and the us

with here and ordinary talked us for line time the of this what for do. plan to lower-cost some out nothing we now. big there's to able its enabler design The right in So be about we transmitter

to going You're see fourth start that in the play through to quarter.

the have the an done system. of out teams So incredible designing job cost of

half will back to produce the We start year. the in of that

You'll a up in us will bit, through quarter, play fourth to inventory to hung the start get produced to actually it benefit the through. start and third sell start in quarter see in get that'll we will the

the with know that you in line So plans had. we it's

I most positioning gives stick do year, be the we strategic ultimately growth think let's I about XXs continue in of kind the terms flexibility to what how need the But in mid of ourselves. give significant in those we environment absolutely that of at to I would think us to you, the flexible do think time, these and point pricing generate to the tell it’s and it next just that things navigate Company. opportunity this

Operator

Morgan. question And JP our from with Marcus comes Robbie next

Robbie Marcus

iCGM? top question there will or great it a alarms your and for potential want today questions it question. And to for investors and how X.X clarity your get of I and GX? What give stock out lot Libre product you to taking the of Does us a impacting of product. So a be approval quarter, here a been appreciated. any much those like? love address the competitors on intending there GX looked is mind compare about. I'd and lately could as insight thoughts eventually would clearly and the is as that's get alerts that's versus Congrats And thanks

Kevin Sayer

take I’ll one. that Kevin. is this Robbie,

can time did very a and first at fact give back bit this be best standards years. talked for guidance in interest wanted guidance was we that. and we the go that and remain bullish Let's develop stand iCGM standards for standalone future will by which a on that products We the us we and we a about time, it about by in FDA the the patients the safe year-ago of the the our and

get to the this the they've and what that get game with obviously So, would iCGM actively bar that. would process that that provided others in the FDA. that started look in the on on, We so world does at evidence assumed event never have eventually standards the to when enough approval we clinical shoot at know iCGM only approval we have and it, is their to be do that we we company the

and our as good somebody a a offering good way. are at today DexCom. been over have the the here, leads aware again I've Realize as field preparing in look the the the aware Ever a But proven as technology always those be claims never as from DexCom they as good since call. is and field always over and DexCom. that you the and for you'll else our as about If used competitive companies the claim of to back company at as this as been had history we've we’re we in good reminiscing as company another notice

has body actual do and the position on performance has that. always us Another world been to on and always best clinical surprising given the real patients

do very extremely of and will will it confident will top line are We the that and received. our product well remain be

not where have seen We X in of launched. Libre Europe a been lot it’s

we have the to not of ours. answers and products. lot for their speak of characteristics We a know don’t lot we're a about So going

one have the intend GX making the best that our patients, we things can offerings overtime to size we the other support. either And experience year advantage have system a lightweight piece We of a we're nature been the I decision it's snob. don’t of its product the -- you better put for to possibly to know than move is over from course to quite offer patient as GX the we -- of body experience and a of wearable, as and the a have the coming even enhancements patient the transmitter always GX. GX with been for It we our many it the the and now I've bigger in but in bit it's leap a history. in GX, where previous GX component anymore, sensor When have

we all So, competitive be benefits a and know and that current will have system more. product the features widely GX of and

So, a pipeline we great opportunity market and one. and -- is participants fabulous, of is there it's our number room not for number just a products of

Robbie Marcus

cost That's the far just a of what Appreciate And But follow-up, us off can not your Kevin. payers you a cost clear. the Are really discussions adverse improving moving patient outcomes? on some diabetes and maybe thoughts, with denominator here? events simply of just like? to reimbursement flavor focused payers too Or then are they bit. give are lowest focused a on avoidance

Kevin Sayer

onus forward, endeavor really to we a and all real-world that logistics first an our our in was avoidance. with very years I be look ago do able the my through for will we platforms coming issue releases they over have years well payers the for great that's time local data that the how better over remarks put and range very successful for get about compliance think our believe patients But a coverage. that now talked normal can strong to discussions more example servers coverage rather first here to the that We've some we make the better couple our this mobile build as in would us. wins been we lot hypo do It with time prepared just from and evidence We gave those measurables a and we course in payers. study payer. job as a on have of clinical have the and do that type it's we're and because alert playing in Diamond will type predictive than systems. know Cigna on we data presented on past can the benefit. we not to it and we our outcomes of mobile GX how now and develop we reduction and discussions and comfortable that we us on very alert. had past several system evidence a from I haven't so evidence every of data have spend back payers time significant in hypoglycemia in do depends do us we much time system at payer discussing on that pharmacy going case, get coverage payer We're that gave seeing just of pharmacy data, that example. the on business of the and as outstanding. We something win the We need depends the of we I patients our and numerous we realm just to our for that time that's provides meeting we pharmacy of taken place. better because are because That the some really us months and contracts I outcomes in is educating that the device press and

Operator

And Leerink. our Antalffy Danielle from next comes from question

is line open. Your

Danielle Antalffy

and and/or new sort but up say a of you Anything around MDI are actually impact question to on a Just this domestically following adds the you think that? or percent to is just and potentially of directionally what question you the getting of on competitor any on can curious color give the iCGM, have MDI said patients not can DexCom you base pumpers? historically today are pumpers. patient your I that of the coming majority the installed versus if

Kevin Sayer

as in patients. significant primarily who will going have as new patients patient reasonable margin, are we're now, well anticipate as get by see just deliver The improve new growth the patient MDI base, can systems we're new Danielle, the over But are now majority the a much of pump new adds getting on larger our but more partners not of insulin, systems do outcomes. we out are Right more I for MDI adds. than that our adds our into a as those systems that segment actually algorithms that

Danielle Antalffy

a expecting And go the you how of to want to tell correctly premium? you do know. Or further in line outlined a you past you're market question said I even GX, understanding pricing expecting with At look me to strategy eventually but change if to be haven��t then GX I'm you the sort point, as is sure and that guys down your the Are at still think GX parity you to beyond? pricing be this well, think and we just pricing I down, that know going is competition make to on be, per se, I at you'll the some with with correct. GX

Kevin Sayer

I am at details outline here's patient. revenue look is here's appropriate regarding per at per what look not the that, charge all but We program patient the our year to annual we and that. and going amount strategy how a the specific to

offering gone we as of With GX, how GX variables rather to For price at revenue a annual that's lot respect GX example, components. to we've individual how pricing product the involved we there's as from year here. that on look per than

justify tools support it that a to premium, decision outcomes. does a better lead have We Does not. that

overtime. it think I to will see have we

Particularly the manufacturing basis Let's we’re that can for for the commit we go, than We you what's study will our a great very work, specifically the got anything that anybody be flexibility we before the have but and this about to very design important can't cost market a decent optimistic have do lower we've prepared today. will Kevin. a of directions markets offering lot from changed community so design now. with we length go. extended cost we product but We're with a all now a what that product we investment I have we to

Operator

P. next question Jaffray. J. from the comes from McKim Piper And

is open. Your line

J. P. McKim

ask you to wanted I Kevin a that now, me. I wearing one that comment a you little just more made -- you’re it feels GX to a so real think,

is will on Or And see still for so, this maybe that will then year? GX start we a that trial in happen And initial thoughts that? something XXXX?

Kevin Sayer

it to respect trials on features probably their much the existing we're me we small The legal people learn is system. gathering pretty experience, first, the wearable going with is GX trials that tune the time, there is all and but guidance the data body. of regulatory but with Look, your really With spectacular. fine to to kill run not

it projects is ever because, would would what biggest started we've and this XX week, and in people have this we're all ago, that CGM would so and involved when huge if this and design been this kudos to in leap this I it’s my with have I attempted innovation Yes, years at I a we’ve look we've As company, leap started the I were term to designed taken finally during in here. business. hope I the

J. P. McKim

should we do Is you -- mean, just define it maybe as data I how Matt programs. is affected of on around, on -- our on that do you really be payers several then recent Or -- at trials? or And going amount those the I should at Or success it time the ADA trails are we arranged just how look either successful? in some keen how medications? see -- how non-intensive guess metric? those you The the trials to with do Kevin, they

Matt Dolan

of of hyperglycemia a ICU as actually, reduction the of length general going to Yes, drug reducing length market. stay, in out exploring on to certainly old of glucose down the opportunities step I'd effort to And ward there. and at take non-insulin some the out as the these market-by-market, in you important love into have individual tolerance the to CGM markets non-intensive trial but take the as radar forward Gestational nursing I the product. getting and to that’s so the cost of as time stay, diabetes, paramount. of important the hospitals still on down early of metric into people say, hospital fair Right, reduced for of important is using ward reduction hospital. becoming the you test hospital point, important type that increasingly CMS and in hypoglycemic some to is session time would work market, and a setting going the in look clinical kind in and we're days that the key prevention our is replace in will actually tell some

team X X next tackle opportunities, the important will to to markets markets. years over And of has robust So size is several and new fits for those pretty develop developed all but in all years increasingly there a the time to markets development Matt kind continue us. this one horizon, become no clearly

Operator

Lewis Stanley. comes next Morgan from question our from David And

Your line is open.

David Lewis

both Quentin, pretty innovation seen powerful I as number just it I if LRP margin. aware conservative scaling that you kind take think XXX the appreciate innovation the are about of now given back the year a actually higher? which it's want in XX% that, being points XX. But it in gross of safe in factors that to come half back about to materially year. of role basis the and mid-XXs I you’re XX% scaling is assume to obviously you with earlier back those number XXXX to to your like commentary so next that Is playing number XX% feels XXXX half a but of

Quentin Blackford

and it's out Yes, whether I don’t want five out to now talk to conservative or years about get from aggressive.

a profile profile. able margin revenue a what very think business to you prepared margins between the for that, more still mix becomes of aggressively sight are lay what variable gross will very address very to through to to efforts I attractive try that out specific lines be bit the to And some of patient we leverage time, of our we higher going address headwind. the clear than a and we're that channels, more drive produce enough be we're as very different GOGS that going is improvement able per over gross to have

at, benefit has back things the plan nice So, from knew year that this in a we’re cost see of something the always are where lower been Kevin's transmitter for we’d with half earlier. that we happy and point coming the

see of headwinds gives in GX come that from as that’s to to the be been us of that You're a the back to us as opportunities more There's out going design there. cost well benefit leverage nice front an lot be the might incremental effective. coming some of

David Lewis

I can last a relationship. much. about U.S channels on provider provider about pharmacy of and XX% preferred relationships pair follow-up are sort And on quick any mix made specifically whether think you see the the into it where you the impact of update first preferential the the benefit we coverage? was are lot us maybe preferred more in forming quarter, benefit are demand? provider you Just into the dynamics, Can provider? or where what of you Thanks pharmacy quarter the future primary Steve on in talk you -- sort of would having relationships provider say so of how you and

Kevin Sayer

status, certainly we’ve I to no. benefit. will answer part is, to as second negotiate pharmacy the a isolated companies trying which trend of answer I that something as of the question preferred we're seeing instances seen the mean some we first but that not move for

XX%. As for commercial lives coverage, north under certainly we’re of

We in to haven’t patients more still we're given hard We're terms a business. commercial pharmacy that number point. of processing through more and XX% than this move not channel and the our more granular close in at processing working that not channel. We're to

have north certainly not XX% processing when of lives we we’re So we covered, the XX%. commercial still say

Operator

BMO Wuensch And from Markets. the Capital next from Joanne question comes

is now open. line Your

Joanne Wuensch

nice very June, really for be taking for us ADM a feel you in there? for at the give should the Thank you meeting quarter. Two looking can what questions we question

Kevin Sayer

that Steve, one? you why don’t take

Steve Pacelli

that I if at a data with at iDCL combined should see data Tandem would least we a deal data. to be the first get most at ADA peek, that will a hope full-blown not we set the say exciting if set where you together really will

TypeZero So, pump and loop GX the Tandem’s the again closed that’s system. DexCom’s running hybrid XX with DexCom algorithm

and from and probably forward perspective highlight that’s to. data additional what us really looking the ADA. There at of a be but poster some for a that’s collectively So, number Tandem for we're will podium presentations,

Kevin Sayer

the that stands going we're just on up I to to going thing is CGM, Joanne is speak every starts see CGM Yes, every of add with believe becoming about continue outcome, board. much talking is other that’s anybody's to everything will evaluating trial, continue to care and And standard trend at everywhere diabetes see the CGM done. everything well ADA, and pretty that you I done across are will the going clearly

Joanne Wuensch

Growth markets. do again question into trying there an of That's quarter to has to might helpful. get second And and with strong I'm you into? be to venture idea looking my was other regions and then this what sustainability just

Kevin Sayer

about You OUS the were market? talking

Steve Pacelli

International.

Kevin Sayer

of where example. range in new of significant example. Korea out of opportunity, the the but next we it’s amounts saw at Japan us in Clearly, in part We is the Asian markets there of And exist to of huge the the Nordic in of expect saw overall out approved nice into overall for coming there of tailwinds some contribution another for haven't of a of of We you probably online. for coming this the just marketplace, was year. then and performer our front and that was and think and yet, another course us, significant markets there strong primary significant you Australia CGM add are started that into sub so still us. growth adoption I is long that later growth markets look continues will coming core amount markets terms over year but get XX% contribution in way leading Germany drive And continue the a that the to to standout growth today. incremental quarter reimbursement see runway the for

So, today a that that growing in or is in there several is and relatively new even markets market untapped it a growth opportunities at paces rates market of incredible opportunities. were

to means at XX% our to range the plans several think the to going in U.S. the business to there is it's make continue growth business think end growing to that available faster the XX% closer I it than there for I get of which So, will in about where to is of long international channels point we talked business to that overall a it overall be that channel lot us.

Operator

Margaret comes from And from Blair. question next William our Kaczor

open. is line Your

Margaret Kaczor

several quarters one we've patient first more strong picture now of because bigger for So me is growth perspective that. seen

CGM that really it’s is the So for or go most what GX is patients or more to becoming pharmacy I'm change guys seeing prescription about and expected in widely you Type whether a in are market patients? irrespective patterns X whether a curious endo in

Kevin Sayer

it's more board widely somewhat the not while this board. the need penetration manager number the across are In patterns a it's arising I worry. believe and type and tool insulin to the point it market we and it's accepting towards that U.S. more is in back rates still becoming think Margaret, is step we in either. one It's at delivery much still Kevin. type insulin and the where becoming the becoming across and not XX% rates prescription just bigger the in the two are intensive range using accepted penetration

unfolds GX connectivity drive all to for and the low to feature were calibration it we because are a insertion to go I of markets to the overtime as were the is But in things GX the to international built here on was population these impact plenty market we is that very forward. it rectifying has for mean we front and rates the this intensive accepted had or penetration runway go more into that market us seeing venue design before So much then easier continue it use easier Huwaii. there think is positive benefits think much at the we

Margaret Kaczor

most so launch improvement see a benefits and they new do the to need don’t it I year it I hardware. connected on have product mentioned know follow-up the think this guys digital like that patients just if you what seems for nice in maybe else you or that end software the will of got selecting you was And from that know that

Kevin Sayer

pumper, anymore. CGM tell would certainly I and several patients I doctors say ask where went folks varies for you you with the we not say it’s here, a I on would in out practice-to-practice still a are all first where who anything doctors identifying different rapidly. varies having and of It changing I It's the there start they interesting recommended from When just I somebody is when is put the Patient time of CGM would started that case was not criteria field guideline like is the some field the standard I do lot territory-to-territory. pump spend only different the this with

be. it varies it it of board so plenty more used equivalent is to across room. but And is There the then still much

Operator

question next comes Johnson Baird. our Jeff from And from

is line now Your open.

Jeff Johnson

go Kevin, talked earlier. the and to on ask a about was I MDI you versus want mix question pump that back

wining MDI the in have change competitive any Are CGM patient native you're side. category, you MDI within that especially you there? base or seen any on those all first-time convert that wining that You of users

Kevin Sayer

a I here. don’t have good piece data of

Kevin Sayer

field but Yes, I on force, stories people our national you an out DexCom, a are that system Abbott market sort That line. sensor sales to we standalone hear with they would who Medtronic, a say our meeting the coming migrate and respect place obviously out anecdotal anecdotally have With so conversion in system the see do rate launched talking we content that DexCom. ask obviously experience all. would any try of at do to of what a really with they front to Libre just they’ve but you body have we we on on that of if give experience don’t metrics and don’t real to you to kind

Jeff Johnson

be there Any update any channel. been Just rates that? that on enough. helpful. quarter. would later demand didn’t get on color then I this much trends GX Medicare, like Fair demand? on on And that impacting Has this year on so things stick that in term we know updates push Thanks. is your

Kevin Sayer

we're Jeff. continued I full. what there, trends say we’re encouraged very to very the I rates mean stick would remain new in there very, by seeing be high. and change incredibly No face our funnel

the that into not that has later we’ve out year in seen trends launch impacted any now. right business GX in Medicare the the pushing So,

Operator

from Schenkel next comes question our And Cowen. Doug with

Your line is open. now

Ryan Blicker

is Doug. questions. new Thanks for for first this on congrats now the Mike Ryan taking And my of role. Hi,

expect And detail? new call. metrics Should Can algorithm expect we GX XXXX? enhancement call. to year the improve You the in XXXX? algorithm then, this about any referenced wear GX we noticeably earlier during performance last coming provide GX I extended talked more you should quarterly during of for the on

Matt Dolan

rest kind we would we tell keep we you the don’t new Do in those there fall commit we're commit around and outlay afterward let’s to that for those will very resources out map. to U.S., things do leave to cases, expect know have us GX we require that many all that on making GX? over decisions in extended those the can -- The before nature out choosing we everybody. resources of we're going And XXXX GX. in features interesting. accelerating I GX You extensive But -- we’re with the way what, close GX we road are an In that wear coming the of acceleration for in XXXX. trials to we’re Or that. are the

Operator

comes question Pasquale your And from next Chris Guggenheim. from

Your is now line open.

Chris Pasquale

out, the on have XXs? months? of forward, the much the what follow-up next it assuming about flush the year. number? pharmacy about And the maintain how dynamic of do with call Going a that XX% is margin, we the a assume comments next continuation kind to Quentin. some shouldn't And But want of you in just you are Just thinking XX good has gross upstream to why mid to margins I’m

Quentin Blackford

here Yes, what to that into the the now, of I'll somewhat last just we we without well. maybe one considerable feel which year business on dynamics around to is specifics right as getting saw point XXXX

moving talked the into channels, some of headwind margin XXX other revenue pharmacy For the these a full and about we relative they’re OUS. both patient roughly to we impact points basis set expectations, per year, when being of

but that’s XXs around opportunities clearly lower to we we will future. to probably know we be we I the year, year. the the next way the It in to us right think thoughtful roll transmitter. based point continue refine start into Clearly, headwind more into gives learn upon with the about as this into that that think they exit push at as up what price to strategies we pricing as time, more

So I but for couple in of now come pressure the back channels, we're we're into what mix from the the right the time points terms why basis being, is mid-XXs that's of feeling seeing. XXX

about think long-term. way it model think the you can still where of the want, from is to right mid-XXs there but you So I

Chris Pasquale

see candidate want you go markets, be little before that data you of is you am the while going these after most new there is guys think indications. on real new But think assuming then lead some and this a or a we I And that this some first? is at point, to promising to

Kevin Sayer

with already non-intensive I the about characterized X. work studies, would Healthcare multiple some in commercial as we're pilot of XXXXs patients. some say type doing mean extent of we're United the we're we've to I talking particularly but

there United, going done any So large are the are to pilot studies. respect With to et work being Onduo cetera, see by not you data.

as indication findings well. But and indication our now, markets that that, data to the proprietary, we’re are hospital, formalized if or to, potential highly more to share we plans that the To going gestational right not clinical there extent, of some available. to a hold for had I hospital going a become with that they to they anybody. fact, so the don’t run the to and In be I something any learnings tip those may have at like competitors in think grow protocol

Operator

Raj from our question And comes next Denhoy Jefferies. from

Your line open. is

Raj Denhoy

want in income leverage we Just to about statements. the ask of middle the the

the how of customer guys such is talking data couple in can of maintain move Philippines transition more environment You if as that you suite. that? the your you appreciate I'm now for that guys service now, kind are competitive, sort and there. is, has of offer as so, if and on And comments about terms or a is increase getting strong have of anything been really you how potentially the of concerns always really so one folks about And you any the think curious that offshore One the in going? questions I

Kevin Sayer

and to built there, Yes, impressed by very but only incredibly that’s team also Raj, over paid attention we metrics, and close been performance the not being we've assessment quantitative qualitative.

single are you gate, with to we domestic every and we've our with the the we what so, can of can over as better. try than they scores And there, tell calls qualitative work higher feedback our seen them out our folks what teams. get opportunity patient from do And on went I take to in the how

seeing have From perspective, to great attention an there. we’re close something been efficiency stages might in and be paying early honest we're quite results beyond we So, what the to. anticipated been recognize that we we've very able to

efficiencies it's and advocacy of look more tech You functions that of our make believe out much much are or quickly, back clearly effectively. and easier significant lead some customer to area, at that support and the complaints office more our coming going other scale, to to the work us it and

believe be encouraged So that what allows by more aggressive the and markets asset we we to strategic of becomes real in how that a effort overtime us in already. local just out about compete are couldn’t we I strategic opportunities this be want seeing we're other company that we more to think in or pursue might there. and to how markets we that

by encouraged what I'm seeing there. So very we're

Operator

Ravi And Misra question from your next Berenberg Capital. from

Ravi Misra

My first on gross is one margins. again

shift And little maybe the us they’re first margins give you or or up maybe what Quentin or ramp? hoping are the could going between showed the then mix that in follow overhead? break year-over-year bridge quarter it headwinds to down versus fourth underutilized that Just quarter, quarter versus a and first on away

Quentin Blackford

talking to Ravi, when this fourth talking you’re QX quarter, you're ‘XX. of year about QX from

Ravi Misra

Yes, that’s exactly.

Quentin Blackford

Sure.

me spend of the the XXX talked we early what impact contribution doubling we some let to anticipated. P&L being of capitalized pharmacy some basis what the not U.S we run through we point with , and on So, continued that anticipated had, and I the had capacity to XXX of shift mentor had that that demand forward bigger so that or QX able beyond headwinds about fact a and points related about is year-over-year its there some pull accelerated just of associated there of real fast, so bit and that overall the all we around about focus than is part of with the really think, our is towards basis business thought QX were

bit while QX in improved fixed going So you're you're just I manufacturing put getting capabilities I we the to in start the get design that watermark QX leverage and right the you're automated or of place what going of the I to benefit of the to think now that really cost leverage overhead low will drives QX transmitter. the a some overhead low be and the QX will improvements on place and find benefit benefit the of to QX of see see in in get to that start you think QX fixed really that levering real and some

gives year XX% the a think terms we for close the bit that hopefully range So clear of the bridge us to as getting you see of of a over contributing side course I what can are in but of line of year. factors the

Ravi Misra

prospective. ask and ward, commentary proposed the payments, around meaning CGM from my some of you what that just on around reimbursement to usage curious patients can technology Then for add the designation rule follow-up the an from I to the around just thanks or second your could some products moving from had changes that on a new fit Great type question and what off-line. is the X is do ward a take you into see space

Quentin Blackford

setting in renewed in a hypoglycemia particularly as a as Absolutely, huge as focus and mentioned, setting the hospital problem. identified has inpatient I CMS

are going finger detect stick a an hypoglycemia you’re So, sticks to with not of finger hour, you if even taking right. couple

put application So, get there can that patients, the opportunity nature on get and reduce there. perfect get CGM there. I CGM We of preop recurring long environment. into these hospitals disposable times, think product into think it, the problem to hospital great the idea the would be in quickly on We of put out perfectly possible. under the them feeling hospital as blood we CGM plays is on, that get potentially GX procedure know is and think and in get sugar a the the also sensor with control them the is We the already as hyperglycemia before

Operator

is next Matt from question Taylor the And from UBS.

is now open. line Your

Matt Taylor

of from your embedded the assumptions want the to question more little give has if on, you So revenue year? stroke a bit guidance changed sense but question, that of of You a detail this what what terms different for in just that little ask give Quentin pricing bit some could will see the component provide the the I can us sequentially a in earlier about address you the are if us from did and for you broad headwinds, can a helpful? changed be

Quentin Blackford

volumes it’s a that Yes, adoption and the that honest incremental comes volume the or simple with the are not increase down think the it lot driving was in I to new marketplace this coming really QX business be we quite it's it patient pieces so confidence continues see anything to the to strong continue really growth. you, it’s in demand in QX. else technology of the our This and in up new patient of different moving

on that business from lot through the strong channel the think as ends experience, a the I see international then that is through a pharmacy commercial up our we majority for but that bit showing well. business of you'll that believe come up and

about So of XXX those it's The channels I patient the all it. assumption no the in talked of driving that pricing at change and the drivers million day volumes end the primary new are are terms headwinds. earlier, two

Matt Taylor

on head things just think to be strategy team. of really able the change the which you and of new And talked Company talk then about the you going you markets the here or at new markets it's to day? and about follow off to Can for up in just maybe near-term those since some the can investor share that's bear fruit you the for with

Kevin Sayer

the not revenue I'm bearing long-term on as case. side, as am concerned building a fruit I

better now for And steps going done a we sitting said echo well. out we patients efforts becomes step GX, early will that, Steve earlier and to we XXXX. out of commercial we again shows you I to And base more save some working delivered had return. best than these in over you the to outcomes roll that not formalize it we're that models those working into the been to this and that haven't other Right we've roll in efforts out these developing where our now year rather go my need we our to we're these people group expect then a a that have that earlier as markets guys quit said taking just have this of like sometime that on remarks establishing these thing. will business evidence rolled new some this and nine projects distributing cost relationships a when something on evidence, places that a we are around as structure go and done. markets as as And to So is as just XXXX outcomes to so the and have be while some and prepared are start get goals develop progress what I've measuring said this in going whole we're expecting more largely

Operator

And the Lichtman Oppenheimer. next comes question from Steve from

Your open. line is

Steven Lichtman

to like patients? X Kevin, think do you at type with payers color on where those spending discussions intensive wise on today were your penetration access any updated and commercial

Kevin Sayer

using very I We gives a it's think is the basis start. can general. with than certainly deep continue give us rolling the CMS that that and I don’t think number XX% very less penetration I to pursue in payers right the you now for as a good there

grow to coverage forward and pay spend referred a outcomes far look it, companies this insurance for extremely getting to of been good are money where I opportunity more use so our we tremendous so it's more Quentin happy simple. we and it good both never with is us it, Medicare we very us tell forward launching as more they patients so getting are it's those nice an X we is Medicare Medicare the of significantly can in future. -- at example you have X as type on system lot launched going and we and we to the into that's year a later patients, patients for the the that However I opportunity opportunity a for patients that the stickiness intensive GX in look think to type are intensive to

Steven Lichtman

the And positive about you the benefit When the see do there? alerts. you predictive hypo think and we are talked results could aggregated then, seeing you around also published from data

Kevin Sayer

already hypoglycemia the has Steve was the believe that alert presented patient GX with predictive predictive paper with so been hypo at experienced alert. ATTD, that’s the I add

Operator

next Securities. Northland And the from comes Suraj Kalia from question

Suraj Kalia

great quarter. afternoon congrats Good a everyone on

love of versus FYXX? So into been speaking, questions this all lump to lot will on bump And gross XX% me roughly XXX, gross up margins for is margins a taking expectations to tells for you Maybe I US. what parse are if should questions you would kind my of kind the the Thank asked, the QX, U.S. some margins think you possible. would just be? would have the from And call, mentioned us, incremental the two maybe the over buckets my get be we How would forgive if is out can how to I expected love transmitter have buckets? margins both you different finally gross this? little for get one. how transmitter? remaining of roughly OUS some OUS, would me the the contribution these that in questions. to the math what I that will this about my be different contribution color, perspective XXX in for for on see And

Kevin Sayer

of in what to U.S. is the to OUS teens terms we that’s the XXs in the OUS which mid growing high of infers business full range, business year year. on so split expected expected course full about on the the in or XX% our U.S. versus grow the so Sure, the that

data We revenue haven't that not to there. mix shift the based just honestly business there now. to going you a so those quarter the fluctuate you to upon It we're right out put And business specific gross given got we put says just the are marketing, on got based a point mix, out OUS margin that and and going U.S. we nor data well. direct of haven’t upon quarter distributor OUS the within point

more exact that with cost can In specific GX the transmitter, we terms is the cheaper incremental transmitter cost the differential of GX than associated the XX% you what giving without you existing transmitter today. low tell benefit it's the

benefit I us margin drive for fourth magnitude timeframe overall think of orders talked quarter that of in a that significant the gross terms it the improvement we in is So very about. clearly in

Operator

over turn back the concludes that I'll for Sayer final to question Kevin the And call answer session. and remarks.

Kevin Sayer

often over on the has million revenue actually but everyone thanks anticipated we Thank X in environment the offerings year, all call I way the areas XX% space but think pricing QX and stop forget being one two recent extremely space we the Much plus wellness. I down we in to This keep opportunity last and it would upon not only going. decided call The wanted in market looking you thing. is things. the health call huge, much at incremental for and competitive today. the this large and in space the too type focused to around growth of months very XX in is of also other at insulin discussion in were and

on but now a forms We getting some CGM then because on interesting and at here team gone Cigna, and and well. see in talked has that multiple tool management across to pricing, in using of win intensive want our all respect cylinders people very see about I configurations to truly the they recent impaired we're well channel are of cash continue when and prescription hitting doing We truly and healthcare standard buying care the manage teams are useful paying it, side seeing very diabetes. DexCom. the all a they system our With earlier the that very and things. with their to becomes nutrition very

other move opportunity to With in GX, the offering knew would technologies forever. respect and GX increased their environment we CGM best all technology the and I come, enhancements sole the to this voice it'll Given coming that. to technology as needs the remain patients that generated by later size be the of We our plan year, DexCom. always gen with that remains the didn’t competitive said next expect the our meets parties awareness following an earlier,

space for the have the everybody expect and this very in a long time. leader in industry We day. a be again Thank to great

Operator

you disconnect. Thank for now concludes call. conference Thank may you participating and you, This gentlemen. ladies today's and

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.